AstraZeneca, Daiichi Sankyo's Datopotamab Deruxtecan Plus Imfinzi With Or Without Chemotherapy Demonstrated Objective Response Rates Of 77% And 50% And Disease Control Rates Of 92% And 93%, Respectively In Untreated Lung Cancer Patients
Author: Benzinga Newsdesk | September 11, 2023 04:29am
The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
Posted In: AZN AZNCF DSKYF DSNKY